Sugi Predict

Sugi Predict / Compounds / SCHEMBL414810

SCHEMBL414810

SCHEMBL414810

Nc1ccnc(Br)c1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ USP2 O75604 1/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ NPY1R P25929 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ TDP1 Q9NUW8 3/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ MAPT P10636 6/20 0.35
▸ HTT P42858 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MITF O75030 1/20 0.35
▸ NOD2 Q9HC29 1/20 0.35
▸ LMNA P02545 4/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ROCK1 Q13464 1/20 0.34
▸ MGMT P16455 1/20 0.34
▸ CLK1 P49759 1/20 0.34
▸ NPC1 O15118 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15201483 0.80 PDE3B (0.39) MEN1KMT2ANPY1RALDH1A1TDP1
SCHEMBL3688848 0.80 MAPT (0.47) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL8561095 0.78 MEN1 (0.42) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL18486948 0.78 KMT2A (0.42) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL30622636 0.77 MEN1 (0.41) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL5126783 0.77 PKM (0.42) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL28802588 0.77 MEN1 (0.41) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL4064206 0.77 MEN1 (0.41) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL203785 0.77 MEN1 (0.41) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL8561596 0.77 MEN1 (0.41) MEN1KMT2AUSP2KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10596154-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2020-03-24 — — US disclosed
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-19 — — US disclosed
US-10195185-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2019-02-05 — — US disclosed
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-11-15 — — US disclosed
US-10081631-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof SAMUMED, LLC (US) 2018-09-25 — — US disclosed
US-20180250269-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2018-09-06 — — US disclosed
US-20180221353-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-09 — — US disclosed
US-20180221353-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-09 — — US disclosed
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-02 — — US disclosed
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-08-02 — — US disclosed
CN-102341388-A Novel substituted benzazoles, benzimidazoles, azolopyridines and imidazopyridine derivatives as gamma secretase modulators ORTHO MCNEIL JANSSEN PHARM 2012-02-01 — — CN disclosed
US-20120022090-A1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2012-01-26 — — US disclosed
CN-102325765-A Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators ORTHO MCNEIL JANSSEN PHARM 2012-01-18 — — CN disclosed
EP-2398793-A1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) 2011-12-28 — — EP disclosed
EP-2393804-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) 2011-12-14 — — EP disclosed
US-20110281881-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS CELLZOME LIMITED (GB) 2011-11-17 — — US disclosed
WO-2011057148-A1 COMPOUNDS AND COMPOSITIONS AS TLR-7 ACTIVITY MODULATORS IRM LLC (BM) 2011-05-12 — — WO disclosed
WO-2010094647-A1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2010-08-26 — — WO disclosed
WO-2010089292-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) 2010-08-12 — — WO disclosed
CN-101384593-A 3-deazapurine derivatives as tlr7 modulators PFIZER LTD (GB) 2009-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10195185-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof WNT1, WNT3, WNT3A MEN1 4159/4885KMT2A 3065/4885USP2 3789/4885
US-10596154-B2 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A MEN1 4013/4885KMT2A 3234/4885USP2 3690/4885
US-20180215753-A1 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MEN1 4250/4885KMT2A 4048/4885USP2 3595/4885
US-20110281881-A1 NOVEL SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APH1A MEN1 2658/4885KMT2A 2777/4885USP2 1148/4885
US-10081631-B2 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A MEN1 4250/4885KMT2A 4048/4885USP2 3595/4885
US-20180250269-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MEN1 4013/4885KMT2A 3234/4885USP2 3690/4885
US-20120022090-A1 NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, GSAP MEN1 3843/4885KMT2A 3462/4885USP2 1913/4885
US-20180325910-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MEN1 4035/4885KMT2A 3241/4885USP2 3693/4885
US-10206929-B2 3-(1H-imidazo[4,5-c]pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine and therapeutic uses thereof WNT1, WNT3, WNT3A MEN1 4035/4885KMT2A 3241/4885USP2 3693/4885
US-20180221353-A1 3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF WNT1, WNT3, WNT3A MEN1 4159/4885KMT2A 3065/4885USP2 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.